Most severely infected patients do not respond well to the use of a single antibacterial agent.7 To overcome this limitation, the present study introduced a combination therapy composed of NAT and cyclosporin(CYSP) for patients with fungal keratitis. This evidence concerns the gene BRD2 and fungal keratitis.